德国不来梅 - （商业资讯） - 9月。15，2009-在61之前stAnnual Meeting of the German Society for Hygiene and Microbiologyon September 20-23, 2009 in Goettingen, Bruker Daltonics announces a new framework agreement with the Limbach laboratory network, concerning microbial identification based on MALDI-TOF mass spectrometry. According to the agreement, Bruker Daltonics will be the exclusive provider of MALDI-TOF based microbial identification solutions for the Limbach network of more than 30 European clinical laboratories.
自从在Labor Limbachheadquarters in Heidelberg in 2007, theMALDI BIOTYPER在林巴赫协会的许多其他实验室中建立了。这MALDI BIOTYPER目前正在海德堡，科布伦兹，汉堡，卡尔斯鲁赫，辛根，玛格德堡和诺德霍恩的德国林巴赫临床微生物学中心使用。签署新框架协议后，布鲁克收到了其他订单MALDI BIOTYPERsystems from the Limbach laboratories in Ravensburg and in Freiburg, and an additional system was ordered for Limbach site in Heidelberg. The Limbach laboratory network intends to introduce this new molecular technology broadly as a very fast routine method for microbial identification in additional Limbach laboratories in Germany. Moreover, Bruker and Labor Limbach intend to jointly introduce theMALDI BIOTYPER在波兰通过林巴赫的华沙和格丹克实验室。
Dr. Anne-Marie Fahr, Head of Microbiology at Labor Limbach, commented: “In contrast to previous introductions of other technologies, in the case of theMALDI BIOTYPERwe have seen a very wide acceptance of this new approach nearly throughout our entire network. Bruker is the leading supplier of MALDI-TOF mass spectrometry with a global support and service network, and is thus the reliable long-term partner that we were looking for in the Limbach association.”
Dr. Wolfgang Pusch, Vice President for Clinical Research Solutions & IVD at Bruker Daltonics, added: “This exclusive framework agreement is a major step ahead into a new era of fast molecular identification in clinical microbiology. The last two years have shown the fundamental advantages of ourMALDI BIOTYPERapproach for microbial identification, i.e. higher specificity, faster time-to-result and lower consumables costs. Moreover, theMALDI BIOTYPERhas proven to be robust and easy to use in demanding environments. We are very pleased that ourMALDI BIOTYPER满足领先的临床实验室的高期望，例如劳工林巴赫协会MALDI BIOTYPERat the upcoming 61stDGHM年会。”
About the BrukerMALDI BIOTYPER
布鲁克的奉献精神MALDI BIOTYPER解决方案可实现分子鉴定，分类学分类或微生物（如细菌，酵母菌和真菌）的消除。使用高通量MALDI-TOF质谱法蛋白质组学指纹识别微生物的分类和鉴定是可靠而快速实现的。应用包括临床常规微生物识别，环境和药物分析，分类学研究，食品和消费者产品处理以及质量控制以及海洋微生物学。布鲁克的强大MALDI BIOTYPERmethod requires minimal sample preparation efforts and offers low consumables cost per sample. TheMALDI BIOTYPER可在某些欧洲国家/地区根据欧盟指令EC/98/79在IVD-CE版本中提供，并在IVD-CE版本中获得。有关更多信息，请访问www.bdal.com/maldibiotyper.
关于布鲁克·道尔顿学
For more information about Bruker Daltonics and Bruker Corporation (NASDAQ: BRKR), please visitwww.bdal.com和www.energie2point0.com.
CAUTIONARY STATEMENT
这种新闻稿中包含的任何语句t do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to adverse changes in conditions in the global economy and volatility in the capital markets, the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, intellectual property rights, litigation, and exposure to foreign currency fluctuations. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2008, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements other than as required by law.
Photos/Multimedia Gallery Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6048603&lang=en
Source: Bruker Daltonics
MALDI BIOTYPERMarketing, Bruker Daltonics
Karin Hoffmann, +49-421-2205-2041
kho@bdal.de